CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN...
Phase 2
Gilbert, Arizona, United States and 8 other locations
the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with...
Phase 1
Phoenix, Arizona, United States and 2 other locations
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows:* A Screening/Baseline...
Phase 3
Tempe, Arizona, United States
In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local con...
Phase 4
Scottsdale, Arizona, United States and 15 other locations
The purpose of the this study is to see if the use of a PET scan with 18F-fluciclovine (PET or Fluciclovine PET) in addition to the normal radiation...
Phase 2
Phoenix, Arizona, United States
Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the stud...
Phase 3
Phoenix, Arizona, United States and 71 other locations
are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma...
Phase 3
Phoenix, Arizona, United States and 47 other locations
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM...
Phoenix, Arizona, United States and 132 other locations
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are sched...
Early Phase 1
Phoenix, Arizona, United States and 2 other locations
This is an open-label, multi-center Phase 0 study with an expansion phase that will enroll up to 24 participants with newly-diagnosed glioblastoma...
Early Phase 1
Phoenix, Arizona, United States
Clinical trials
Research sites
Resources
Legal